EVOKE PHARMA, INC. Revenue
EVOKE PHARMA, INC. reported Revenue of $4.28 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-11-13
- EVOKE PHARMA, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $4.28M, a 61.40% increase year-over-year.
- EVOKE PHARMA, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $3.75M, a 47.06% increase year-over-year.
- EVOKE PHARMA, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $3.08M, a 77.48% increase year-over-year.
- EVOKE PHARMA, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-12-31 was $3.31M, a 97.40% increase year-over-year.
- EVOKE PHARMA, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $10.25M, a 97.84% increase from fiscal 2023.
- EVOKE PHARMA, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $5.18M, a 106.51% increase from fiscal 2022.
- EVOKE PHARMA, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $2.51M, a 55.04% increase from fiscal 2021.
- EVOKE PHARMA, INC. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $1.62M, a 6929.00% increase from fiscal 2020.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-09-30 | $4.28M 10-Q · filed 2025-11-13 | $8.04M derived: sum of 2 quarters · filed 2025-11-13 | $11.12M 10-Q · filed 2025-11-13 | $14.42M derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | $3.75M 10-Q · filed 2025-08-14 | $6.83M 10-Q · filed 2025-08-14 | $10.14M derived: sum of 3 quarters · filed 2025-08-14 | $12.79M derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-03-31 | $3.08M 10-Q · filed 2025-05-13 | $6.39M derived: sum of 2 quarters · filed 2025-05-13 | $9.04M derived: sum of 3 quarters · filed 2025-11-13 | $11.59M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-12-31 | $3.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $5.96M derived: sum of 2 quarters · filed 2025-11-13 | $8.51M derived: sum of 3 quarters · filed 2025-11-13 | $10.25M 10-K · filed 2025-03-13 |
| 2024-09-30 | $2.65M 10-Q · filed 2025-11-13 | $5.21M derived: sum of 2 quarters · filed 2025-11-13 | $6.94M 10-Q · filed 2025-11-13 | $8.62M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.55M 10-Q · filed 2025-08-14 | $4.29M 10-Q · filed 2025-08-14 | $5.96M derived: sum of 3 quarters · filed 2025-08-14 | $7.53M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.74M 10-Q · filed 2025-05-13 | $3.41M derived: sum of 2 quarters · filed 2025-05-13 | $4.97M derived: sum of 3 quarters · filed 2025-05-13 | $6.11M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $3.24M derived: sum of 2 quarters · filed 2025-03-13 | $4.37M derived: sum of 3 quarters · filed 2025-03-13 | $5.18M 10-K · filed 2025-03-13 |
| 2023-09-30 | $1.56M 10-Q · filed 2024-11-07 | $2.69M derived: sum of 2 quarters · filed 2024-11-07 | $3.50M 10-Q · filed 2024-11-07 | $4.30M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.13M 10-Q · filed 2024-08-13 | $1.94M 10-Q · filed 2024-08-13 | $2.74M derived: sum of 3 quarters · filed 2024-08-13 | $3.57M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $810.41K 10-Q · filed 2024-05-14 | $1.61M derived: sum of 2 quarters · filed 2024-05-14 | $2.44M derived: sum of 3 quarters · filed 2024-05-14 | $2.90M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $796.37K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-05-14 | $1.63M derived: sum of 2 quarters · filed 2024-05-14 | $2.09M derived: sum of 3 quarters · filed 2024-05-14 | $2.51M 10-K/A · filed 2024-05-14 |
| 2022-09-30 | $832.10K 10-Q · filed 2023-11-09 | $1.29M derived: sum of 2 quarters · filed 2023-11-09 | $1.71M 10-Q · filed 2023-11-09 | $2.07M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $461.80K 10-Q · filed 2023-08-10 | $880.17K 10-Q · filed 2023-08-10 | $1.24M derived: sum of 3 quarters · filed 2023-08-10 | $2.17M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $418.38K 10-Q · filed 2023-05-15 | $778.95K derived: sum of 2 quarters · filed 2023-05-15 | $1.71M derived: sum of 3 quarters · filed 2023-05-15 | $1.95M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $360.57K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $1.29M derived: sum of 2 quarters · filed 2023-03-21 | $1.53M derived: sum of 3 quarters · filed 2023-03-21 | $1.62M 10-K · filed 2023-03-21 |
| 2021-09-30 | $930.45K 10-Q · filed 2022-11-09 | $1.17M derived: sum of 2 quarters · filed 2022-11-09 | $1.26M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $236.63K 10-Q · filed 2022-08-10 | $327.06K 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $90.42K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $23.02K 10-K · filed 2022-03-08 |